Full Text View
Tabular View
No Study Results Posted
Related Studies
Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema
This study is not yet open for participant recruitment.
Verified by Rabin Medical Center, November 2008
First Received: November 30, 2008   Last Updated: December 1, 2008   History of Changes
Sponsor: Rabin Medical Center
Information provided by: Rabin Medical Center
ClinicalTrials.gov Identifier: NCT00800423
  Purpose

Most patients undergoing cataract surgery suffer from corneal edema after the surgery.

Brimonidine drops are a well known and safe Anti-glaucoma medication. the investigators have made several clinical observations that patients receiving Brimonidine drops had a faster resolution of their corneal edema even if they had normal intra-ocular pressure.

The investigators believe that administering topical Brimonidine to patients with significant post operative corneal edema will hasten the resolution of their corneal edema.


Condition Intervention Phase
Corneal Edema
Visual Acuity
Drug: Brimonidine Tartrate 0.2%
Drug: Timolol maleate 0.5%
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Phase 3 Study of Brimonidine Tartrate Drops Efficacy in Reducing Post Operative Corneal Edema After Cataract Surgery

Resource links provided by NLM:


Further study details as provided by Rabin Medical Center:

Primary Outcome Measures:
  • central corneal thickness in micrometer [ Time Frame: day 0 (day of enrollment ), day 7, day 30 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • grading of corneal edema (1-3) [ Time Frame: day 0 (day of enrollment), day 7, day 30 ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: January 2009
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
brimonidine: Experimental

50 patients receiving Brimonidine Tartrate drops in the operated eye: 1 drop X2 a day for 1 month.

they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)

Drug: Brimonidine Tartrate 0.2%

Brimonidine Tartrate 0.2% drops

1 drop twice a day for 1 month in the operated eye

2 tmolol: Active Comparator

50 patients receiving timolol maleate 0.5% drops in the operated eye

1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)

Drug: Timolol maleate 0.5%

timolol maleate 0.5% drops

1 drop twice a day for 1 month in the operated eye

3: No Intervention
50 patients will not receive any additional drug to the usual medications after cataract surgery (corticosteroids and antibiotics drops)

Detailed Description:

Most patients undergoing cataract surgery suffer from corneal edema after the surgery which temporarily reduces their visual acuity until corneal edema resolves over several weeks Brimonidine drops are a well known and safe Anti-glaucoma medication, used to lower intra ocular pressure.

there have been several clinical observations that patients receiving Brimonidine drops had a faster resolution of their corneal edema even in the presence of normal intra-ocular pressure.

The investigators postulated that administering topical Brimonidine to patients with significant post operative corneal edema will hasten their recovery and visual improvement.

In order to prove that Brimonidine drops contribute to faster resolution of cornel edema and visual improvement, the study will randomly compare 50 post cataract surgery patients (group A)who will be administered Brimonidine to 2 control groups (50 people in each group):

group B will be given topical timolol drops 0.5% (another well recognized anti glaucoma medication which reduces intra-ocular pressure by different mechanism than Brimonidine.

Group C will not be given any test drug. All 3 groups will receive the regular post operative medications which include corticosteroids and antibiotics.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1 day after uneventful cataract surgery
  • corneal edema (grade 2 to 3)

Exclusion Criteria:

  • glaucoma
  • higher than normal intraocular pressure (>23 mm Hg)
  • known sensitivity or contra indication to brimonidine
  • known sensitivity or contra indication to timolol
  • pre operative corneal or anterior segment disease
  • intraoperative complications
  • major ocular pathology other than corneal that reduced vision (retinal degeneration, optic neuropathy etc.)
  • pregnant women
  • children
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00800423

Contacts
Contact: Anat Robinson, MD 9729377176 robina@clalit.org.il
Contact: Omer Y Bialer, MD 9729377171 omerb@clalit.org.il

Locations
Israel
Rabin medical center ophthalmology deparment
Petah-Tikva, Israel, 49100
Sponsors and Collaborators
Rabin Medical Center
Investigators
Principal Investigator: Anat Robinson, MD Rabin medical center, Clalit health services , Israel
  More Information

No publications provided

Responsible Party: Rabin Medical Center ( Dr. Robinson Anat )
Study ID Numbers: 5189
Study First Received: November 30, 2008
Last Updated: December 1, 2008
ClinicalTrials.gov Identifier: NCT00800423     History of Changes
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rabin Medical Center:
corneal edema
postoperative corneal edema
central corneal thickness
visual acuity
postoperative
brimonidine
timolol
cataract surgery

Additional relevant MeSH terms:
Corneal Diseases
Neurotransmitter Agents
Adrenergic alpha-Agonists
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Eye Diseases
Physiological Effects of Drugs
Edema
Lens Diseases
Cardiovascular Agents
Antihypertensive Agents
Adrenergic Agonists
Pharmacologic Actions
Signs and Symptoms
Therapeutic Uses
Cataract
Corneal Edema
Adrenergic beta-Antagonists
Adrenergic Antagonists
Anti-Arrhythmia Agents
Timolol
Brimonidine

ClinicalTrials.gov processed this record on February 09, 2010